Ridge Properties DBA Pain Relief Naturally Products: Recall - Manufacturing Concerns at the Facility
Risk of decreased quality and consistency (i.e., the safety, identity, strength, quality and purity)
Italiano
Risk of decreased quality and consistency (i.e., the safety, identity, strength, quality and purity)
L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti controindicazioni sull'uso di fingolimod (Gilenya) in pazienti con disturbi cardiaci pregressi.
Il Comitato per la valutazione dei rischi per la farmacovigilanza dell’EMA (PRAC) raccomanda ulteriori restrizioni per il medicinale per la sclerosi multipla Zinbryta a causa del rischio di gravi danni al fegato.
L'Agenzia
Europea dei Medicinali (EMA) inizierà una nuova revisione dei benefici e dei
rischi dei farmaci contenenti flupirtina indicati per alleviare il dolore.
L'Agenzia Europea dei Medicinali ha avviato una nuova revisione delle soluzioni per infusione contenenti amido idrossietilico (HES).
Suspend further administration of octagam 10% from production lots K724B8541 and K725A8541.
Administration of a drug product, intended to be sterile, that may contain microbial contamination has the potential to result in serious adverse events which may include life-threatening infections. Posted 10/21/2017
UPDATED 10/19/2017. St. Jude Medical notified physicians of the Battery Performance Alert (BPA), a new tool that detects and notifies physicians of abnormal battery performance that may lead to premature battery depletion.
Statins are considered the first potential pharmacological cause of muscular damage. Even though this was a well-known muscular adverse reaction, when fatal cases of rhabdomyolysis – the most severe muscular adverse reaction – triggered the withdrawal of cerivastatin from the market in 2001, a massive increase in spontaneous reports of muscular reactions linked to statins followed. Nevertheless, it is important to consider that other drugs, less frequently than statins, can cause muscular reactions.
Over the last 20 years, biological drugs have changed the therapeutic prospect for chronic inflammatory bowel diseases both in the adult and in the child.1 Infliximab was the first drug that, when its patent expired, had biosimilars authorised by EMA, CT-P13 and SB2 respectively in 2013 and 2016.2 The commercialisation of the biosimilars has injected competition in an extremely delicate and expensive sector for the drug industry, with the result that the European Countries have registered a decrease in the official costs of infliximab between 2 and 39%, with peaks over
80.211.154.110